Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03272373
Other study ID # K.CR.I.G.16.34
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 3, 2017
Est. completion date March 31, 2023

Study information

Verified date September 2023
Source Zimmer Biomet
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate clinical performance for the commercially available NexGen TM Monoblock Tibia and NexGen TM Modular Tibia used in primary cementless tibia total knee arthroplasty.


Description:

This is a prospective, multicenter, non-randomized clinical study designed to facilitate the collection and evaluation of radiographic parameters, pain and function, survival of the device, and adverse event data. This clinical study will include the NexGen TM Monoblock Tibia and NexGen TM Modular Tibia as 2 single-arms being analyzed separately. The study will require each site to obtain IRB approval prior to study enrollment. All potential study subjects will be required to participate in the Informed Consent Process. All study subjects will undergo preoperative clinical evaluations prior to their cementless tibia total knee arthroplasty. An immediate postoperative radiograph will be required. Postoperative clinical follow-up and radiographic evaluations will be conducted at 6 weeks, 6 months, 1 year, and 2 years. The primary endpoint of this study is to evaluate the clinical performance of the implant at 2 years postoperatively using radiographic parameters. Radiographs will be assessed for the absence of progressive tibial radiolucencies, as defined in the radiographic protocol. The secondary endpoints of this study will evaluate the clinical performance of the implant at 2 years postoperatively, based upon: - No revisions for any reason - Oxford Knee Score >38


Recruitment information / eligibility

Status Completed
Enrollment 182
Est. completion date March 31, 2023
Est. primary completion date March 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient is at least 18 years of age. 2. Patient qualifies for a primary cementless tibia total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following: 1. Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis. 2. Collagen disorders and/or avascular necrosis of the femoral condyle. 3. Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy. 4. Moderate valgus, varus, or flexion deformities. 5. The salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee. 3. Patient has participated in the study-related Informed Consent process. 4. Patient is willing and able to provide written Informed Consent by signing and dating the IRB approved Informed Consent Form. 5. Patient is willing and able to complete scheduled study procedures and follow-up evaluations as described in the Informed Consent Form. 6. Independent of study participation, patient is a candidate for commercially available cementless NexGen TM tibial knee component, implanted in accordance with product labeling. Exclusion Criteria: 1. Previous history of infection in the affected joint. 2. Active local or systemic infection that may affect the prosthetic joint. 3. Insufficient bone stock on femoral or tibial surfaces. 4. Skeletal immaturity. 5. Neuropathic arthropathy. 6. Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb. 7. A stable, painless arthrodesis in a satisfactory functional position. 8. Severe instability secondary to the absence of collateral ligament integrity. 9. Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin. 10. Patient has previously received partial or total knee arthroplasty for the ipsilateral knee. 11. Patient is currently participating in any other surgical intervention studies or pain management studies. 12. Patient is known to be pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.). 13. Patient has a known or suspected sensitivity or allergy to one or more of the implant materials.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
NexGen TM Monoblock Tibia
Primary cementless tibia total knee arthroplasty
NexGen TM Modular Tibia
Primary cementless tibia total knee arthroplasty

Locations

Country Name City State
United States Woods Mill Orthopedics, Ltd Chesterfield Missouri
United States Franciscan Health Mooresville Indiana
United States Henry County Orthopedics and Sports Medicine New Castle Indiana
United States University of Pennsylvania Philadelphia Pennsylvania
United States Pinehurst Surgical Clinic Pinehurst North Carolina
United States LA BioMed at Harbor-UCLA Medical Center Torrance California
United States Cornerstone Orthopaedics & Sports Medicine, P.C. Wheat Ridge Colorado

Sponsors (1)

Lead Sponsor Collaborator
Zimmer Biomet

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Radiographic Parameters Radiograph assessments 2 years
Secondary Oxford Knee Score The Oxford Knee Score assesses function and pain after total knee arthroplasty. 2 years
Secondary Revision Rate Rate of the number of revisions for any reason 2 years
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4